EIPAF
ENI SPA
$26.05
0.00%
No data for this timeframe.
Vol
SEC Reports7
Recent Activity
Jun 3, 2026
SEC
Eni S.p.A. reported the purchase of 1,771,356 treasury shares (0.06% of share capital) on Euronext Milan during May 28-2
6-K — Impact 2/10
May 27, 2026
SEC
Eni reports the termination of the first tranche of its 2026 treasury shares buyback program and the launch of a second
6-K — Impact 3/10
May 20, 2026
SEC
Eni S.p.A. filed a 6-K reporting the purchase of 861,111 treasury shares on May 11, 2026, at a weighted average price of
6-K — Impact 2/10
Analyst Ratings
5Strong Buy
10Buy
14Hold
1Sell
0Strong Sell
Latest Reports
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
7 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 6 neutral. Avg impact: 3.7/10.
NEUTRAL
6-K
2/10
Eni S.p.A. reported the purchase of 1,771,356 treasury shares (0.06% of share capital) on Euronext M
Jun 3, 2026
NEUTRAL
6-K
3/10
Eni reports the termination of the first tranche of its 2026 treasury shares buyback program and the
May 27, 2026
NEUTRAL
6-K
2/10
Eni S.p.A. filed a 6-K reporting the purchase of 861,111 treasury shares on May 11, 2026, at a weigh
May 20, 2026
NEUTRAL
6-K
2/10
Eni S.p.A. filed a 6-K reporting the purchase of 875,813 treasury shares (0.03% of share capital) on
May 13, 2026
NEUTRAL
6-K
4/10
Eni's annual shareholders meeting approved 2025 financial statements (net profit €4.429B), set 2026
May 7, 2026
BULLISH
6-K
8/10
Eni reported strong first-quarter 2026 results, with 9% year-over-year production growth, exceptiona
Apr 24, 2026
NEUTRAL
6-K
5/10
Eni's Board approved a potential bond issuance of up to €10 billion by March 2028 for general corpor
Apr 7, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution: 50% buy across 30 analysts — 5 strong buy, 10 buy, 14 hold, 1 sell, 0 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $32.9B | 75.3% | — |
| Next Q 2026-09-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $28.4B | 40.3% | — |
| Current FY 2026-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $107.0B | 30.2% | — |
| Next FY 2027-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $95.6B | -10.6% | — |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 5 | 10 | 14 | 1 | 0 | 50% | |
| May 1, 2026 | 5 | 10 | 14 | 1 | 0 | 50% | |
| Apr 1, 2026 | 5 | 7 | 17 | 1 | 1 | 39% | |
| Mar 1, 2026 | 5 | 6 | 17 | 2 | 0 | 37% | |
| Feb 1, 2026 | 5 | 6 | 16 | 3 | 0 | 37% | |
| Jan 1, 2026 | 5 | 6 | 16 | 2 | 0 | 38% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.